[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415447":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Allogeneic HSCT recipients and donors",null,[12],"Diagnostic Test: Next generation sequencing",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Next generation sequencing","Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.\n\nGene mutations and pathogenic gene fusion will be determined in the peripheral blood and\u002For marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing.",[9],[20],{"name":21,"affiliation":5,"role":22},"Harinder Gill, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+852 22554542","gillhsh@hku.hk",[29],{"facility":5,"status":30,"city":31,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Hong Kong","HK",{"type":34,"coordinates":35},"Point",[36,37],114.17469,22.27832,{"lat":37,"lon":36},[40,42],{"name":21,"role":25,"phone":41,"phoneExt":10,"email":27},"85222554542",{"name":43,"role":44,"phone":10,"phoneExt":10,"email":10},"Yok-Lam Kwong, MD","SUB_INVESTIGATOR",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100415447","donor-chip-and-allogeneic-hsct-outcome-100415447",false,"NCT04689750","Donor CHIP and Allogeneic HSCT Outcome","Impact of Donor Clonal Haematopoiesis of Indeterminate Potential (CHIP) on Recipient Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (Allo-HSCT)","Inclusion Criteria:\n\n1. Adult aged 18 year or above\n2. Donor and recipient of allo-HSCT\n3. In prospective and partial prospective\u002Fretrospective case, subjects who have provided a signed written informed consent. In retrospective case, subjects who had provided a previously signed written informed consent on:\n\n   1. voluntary provision of clinical data, and\n   2. voluntary provision of archived\u002Fremaining specimens for genetic analysis, and\n   3. authorizing storage and usage of archived\u002Fremaining specimens for any further analysis\n\nExclusion Criteria:\n\n1\\. Autologous peripheral blood stem cells or bone marrow stem cell donors for autologous HSCT","ALL","18 Years",{"count":57,"type":58},850,"ESTIMATED","OBSERVATIONAL","Current data on the impact of donor CHIP on long-term recipient outcome remain largely speculative. Data on the impact of donor CHIP including on allograft function, immunologic dysfunction, graft versus host disease (GVHD), disease relapse and survival across various donor populations are scarce. This is a retrospective-prospective cohort study designed to determine the association between donor gene mutations and outcome following allogeneic HSCT.",[62],"Clonal Hematopoiesis",[64,65,66],"Donor clonal hematopoiesis","Allogeneic hematopoiectic stem cell transplantation","Outcome","2022-10-03",{"date":69,"type":70},"2022-10-04","ACTUAL",{"date":72,"type":70},"2021-01-01",{"date":74,"type":58},"2026-12-31",{"name":5,"class":6},1]